drugset / Trial / NCT06975891

Performance of Systane PRO Versus Refresh Optive Mega-3

NCT06975891

Phase 4 Terminated 20 enrolled Scripps Poway Eyecare and Optometry Sengi · collab
RandomizedCrossoverQuadruple-blindBasic science

Summary

Single site, prospective, double-masked, randomized-controlled, cross-over study of the subjective and objective performance of 2 different eyedrops. Subjects will be assessed at a screening visit, and 3 follow-up visits. Clinical evaluations will include patient questionnaires.

Timeline

Start
2025-05-15
Primary completion
2025-09-30
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Refresh Optive MEGA-3 Other / unclassified
Subject Systane PRO Unknown

Indications